Приказ основних података о документу

dc.creatorRomanowski, Radoslaw
dc.creatorCulbert, Rick
dc.creatorAlkemade, Stan
dc.creatorMedellin-Pena, Maira J.
dc.creatorBugarski, Dejan
dc.creatorMilovanović, Aleksandar
dc.creatorNešić, Slađan
dc.creatorMasić, Aleksandar
dc.date.accessioned2020-06-03T14:15:00Z
dc.date.available2020-06-03T14:15:00Z
dc.date.issued2017
dc.identifier.issn0567-8315
dc.identifier.urihttps://vet-erinar.vet.bg.ac.rs/handle/123456789/1479
dc.description.abstractCalf diarrhea is a common disease in young animals and the primary cause of productivity and economic losses to cattle producers worldwide. According to the report from the National Animal Health Monitoring System for U.S. dairy, more than fifty percent of the deaths of un-weaned calves is attributed to severe diarrhea. Enterotoxigenic Escherichia coli (ETEC) strain K99+ remains the most common pathogen isolated from calves which are younger than three days of age. Dam vaccination and the use of antimicrobials remain the most used prophylactic and treatment options for calf diarrhea. The rise in antibiotic resistance around the world has been a major concern and new alternative therapies have been explored. Mycobacterium Cell Wall Fraction (MCWF) is a biological immunomodulator that has a potential in multiple veterinary health services such as the treatment and prevention of infectious diseases and anticancer therapy in both small and large animals. The efficacy of the MCWF in reducing the severity of neonatal calf diarrhea and its associated mortality, following challenge with ETEC K99+ was evaluated. Twenty-three calves were placed into two experimental groups. Eleven calves received a single 1 mL dose of MCWF intravenously (IV) at the onset of clinical signs of disease following challenge. Twelve non-treated, challenged calves were retained as controls. The severity and duration of diarrhea was significantly reduced in the MCWF treated group compared to untreated controls. In addition, the mortality rate in the MCWF treated group was significantly reduced to 10% while the observed mortality in the control group reached 58%. Data from the current study suggest that MCWF could be used as an alternative treatment to reduce the severity, duration and mortality of ETEC induced diarrhea in neonatal calves.en
dc.publisherUniverzitet u Beogradu - Fakultet veterinarske medicine, Beograd
dc.rightsopenAccess
dc.sourceActa Veterinaria-Beograd
dc.subjectcalf diarrheaen
dc.subjectETECen
dc.subjectMCWFen
dc.subjectneonatalen
dc.titleMycobacterium cell wall fraction immunostimulant (amplimune (tm)) efficacy in the reduction of the severity of etec induced diarrhea in neonatal calvesen
dc.typearticle
dc.rights.licenseARR
dcterms.abstractБугарски, Дејан; Нешић, Слађан; Цулберт, Рицк; Миловановић, Aлександар; Масић, Aлександар; Меделлин-Пена, Маира Ј.; Aлкемаде, Стан; Романоwски, Радослаw;
dc.citation.volume67
dc.citation.issue2
dc.citation.spage228
dc.citation.epage243
dc.citation.other67(2): 228-243
dc.citation.rankM23
dc.identifier.wos000406311800007
dc.identifier.doi10.1515/acve-2017-0019
dc.identifier.scopus2-s2.0-85021425205
dc.identifier.fulltexthttps://vet-erinar.vet.bg.ac.rs/bitstream/id/439/1478.pdf
dc.type.versionpublishedVersion


Документи

Thumbnail

Овај документ се појављује у следећим колекцијама

Приказ основних података о документу